Marker Therapeutics, Inc.

Category: Press Releases

Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Houston, TX – September 17, 2020– Marker Therapeutics, Inc. (NASDAQ:MRKR),
a clinical-stage immuno-oncology company specializing
in the development of next-generation T cell-based immunotherapies for the
treatment of hematological malignancies and solid tumor indications, today
announced that its President and Chief Executive Officer, Peter L. Hoang, will
present at the upcoming Virtual Oppenheimer Fall Healthcare Life Sciences &…

Read More

Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Marker Therapeutics, Inc., today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.

Read More

Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

Marker Therapeutics, Inc., today announced that it has executed a lease agreement to establish a cGMP manufacturing facility in Houston, TX, in an area near the George Bush Intercontinental Airport. The facility will allow production according to U.S. Food and Drug Administration (FDA) guidelines and is designed to be scalable using modular processes. The facility is expected to be completed by year-end and operational in 2021.

Read More

Marker Therapeutics Receives USAN Approval for “zelenoleucel” as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia

Marker Therapeutics, Inc. announced today that the United States Adopted Name (USAN) Council has approved “zelenoleucel” as the nonproprietary (generic) name for MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product candidate for the treatment of patients with acute myeloid leukemia (AML) following allogeneic stem cell transplant in both adjuvant and active disease settings.

Read More

Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Marker Therapeutics, Inc. today announced updated clinical results from an ongoing investigator-sponsored Phase 1 trial led by the Baylor College of Medicine, evaluating the Company’s MultiTAA-specific T cell therapy in patients with advanced or metastatic pancreatic adenocarcinoma. Data from a cohort of patients receiving MultiTAA-specific T cell therapy in combination with standard-of-care chemotherapy in the first-line setting (Arm A), were reviewed today by lead investigator, Brandon G. Smaglo, M.D., FACP, as part of a poster session during the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting. ASCO is being held from Friday, May 29 through Sunday, May 31, 2020.

Read More

Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at ASCO 2020 Annual Meeting

Marker Therapeutics, Inc. today announced that updated clinical data from an investigator-sponsored Phase 1/2 trial led by Baylor College of Medicine were selected for presentation during a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

Read More

Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results

Marker Therapeutics, Inc. today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.

Read More

Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020

Marker Therapeutics today announced that it will host a conference call and webcast on Monday, May 11, 2020 at 5:00 p.m. Eastern Time to review its first quarter 2020 financial and operating results and provide a corporate update.

Read More

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia

Marker Therapeutics today announced that the United States Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug designation to MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for the treatment of patients with acute myeloid leukemia (AML), following allogeneic stem cell transplant.

Read More

Marker Therapeutics Reports Full Year 2019 Operating and Financial Results

Marker Therapeutics today provided a corporate update and reported financial results for the full year ended December 31, 2019.

Read More